• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于卵巢浆液性癌的二元组织学分级系统是一个独立的预后因素:基于人群的在丹麦诊断的 1978-2006 年间的 4317 名女性的研究。

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

机构信息

Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.

出版信息

Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028. Epub 2012 Feb 24.

DOI:10.1016/j.ygyno.2012.02.028
PMID:22370600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3358352/
Abstract

OBJECTIVE

To evaluate the prognostic significance of histologic grade on survival of ovarian serous cancer in Denmark during nearly 30 years.

METHODS

Using the nationwide Danish Pathology Data Bank, we evaluated 4317 women with ovarian serous carcinoma in 1978-2006. All pathology reports were scrutinized and tumors classified as either low-grade serous carcinomas (LGSC) or high-grade serous carcinomas (HGSC). Tumors in which the original pathology reports were described as well-differentiated were classified as LGSC, and those that were described as moderately or poorly differentiated were classified as HGSC. We obtained histologic slides from the pathology departments for women with a diagnosis of well-differentiated serous carcinoma during 1997-2006, which were then reviewed by expert gynecologic pathologists. Data were analyzed using Kaplan-Meier methods and Cox proportional hazards regression analysis with follow-up through June 2009.

RESULTS

Women with HGSC had a significantly increased risk of dying (HR=1.9; 95% CI: 1.6-2.3) compared with women with LGSC while adjusting for age and stage. Expert review of 171 women originally classified as well-differentiated in 1997-2006 were interpreted as LGSC in 30% of cases, whereas 12% were interpreted as HGSC and 50% as serous borderline ovarian tumors (SBT). Compared with women with confirmed LGSC, women with SBT at review had a significantly lower risk of dying (HR=0.5; 95% CI: 0.22-0.99), and women with HGSC at review had a non-significantly increased risk of dying (HR=1.6; 95% CI: 0.7-3.4).

CONCLUSIONS

A binary grading system is a significant predictor of survival for ovarian serous carcinoma.

摘要

目的

评估丹麦近 30 年来组织学分级对卵巢浆液性癌生存的预后意义。

方法

利用全国性的丹麦病理数据库,我们评估了 1978 年至 2006 年间 4317 例卵巢浆液性癌患者。所有病理报告均进行了详细审查,并将肿瘤分为低级别浆液性癌(LGSC)或高级别浆液性癌(HGSC)。原始病理报告描述为高分化的肿瘤被归类为 LGSC,而那些描述为中-低分化的肿瘤被归类为 HGSC。我们从病理学部门获得了 1997 年至 2006 年间诊断为高分化浆液性癌的女性的组织学切片,并由妇科病理专家进行了审查。使用 Kaplan-Meier 方法和 Cox 比例风险回归分析进行数据分析,并随访至 2009 年 6 月。

结果

在调整年龄和分期后,与 LGSC 患者相比,HGSC 患者死亡风险显著增加(HR=1.9;95%CI:1.6-2.3)。对 1997 年至 2006 年间最初分类为高分化的 171 例患者进行了专家审查,其中 30%的病例被重新归类为 LGSC,12%的病例被重新归类为 HGSC,50%的病例被重新归类为浆液性交界性卵巢肿瘤(SBT)。与经确认的 LGSC 患者相比,经审查被诊断为 SBT 的患者死亡风险显著降低(HR=0.5;95%CI:0.22-0.99),而经审查被诊断为 HGSC 的患者死亡风险无显著增加(HR=1.6;95%CI:0.7-3.4)。

结论

二元分级系统是卵巢浆液性癌生存的重要预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cb3/3358352/4e4f61fef187/nihms365029f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cb3/3358352/4e4f61fef187/nihms365029f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cb3/3358352/4e4f61fef187/nihms365029f1.jpg

相似文献

1
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.一种用于卵巢浆液性癌的二元组织学分级系统是一个独立的预后因素:基于人群的在丹麦诊断的 1978-2006 年间的 4317 名女性的研究。
Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028. Epub 2012 Feb 24.
2
A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.1978年至2002年丹麦全国性浆液性“交界性”卵巢肿瘤研究:集中病理复查及与普通人群相比的总生存率
Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.
3
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.浆液性交界性肿瘤细分为非典型增生性肿瘤和非浸润性低级别癌的长期行为:一项基于人群的942例临床病理研究
Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.
4
A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.一项对1978年至2002年丹麦卵巢浆液性交界性肿瘤的全国性研究。复发风险及卵巢浆液性癌的发生情况。
Gynecol Oncol. 2017 Jan;144(1):174-180. doi: 10.1016/j.ygyno.2016.11.007. Epub 2016 Nov 9.
5
Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.卵巢低级别浆液性癌:对在单一机构进行初次手术的33例病例的临床病理研究
Am J Surg Pathol. 2016 May;40(5):627-35. doi: 10.1097/PAS.0000000000000615.
6
Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.同期发生的卵巢浆液性交界性肿瘤和随后发生的浆液性癌的临床病理和分子特征。
Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325.
7
[Serous ovarian tumors].[浆液性卵巢肿瘤]
Pathologe. 2014 Jul;35(4):314-21. doi: 10.1007/s00292-014-1906-2.
8
Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.联合检测 TP53 和 AGR3 有助于鉴别卵巢高级别浆液性癌与低级别浆液性癌。
Int J Oncol. 2018 Jun;52(6):2041-2050. doi: 10.3892/ijo.2018.4360. Epub 2018 Apr 4.
9
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.TP53的分子改变是卵巢高级别浆液性癌的一个决定性特征:对癌症基因组图谱卵巢研究中缺乏TP53突变病例的重新审视。
Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.
10
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.具有交界性分化的浆液性卵巢癌的基因组分类可区分 RAS 通路和 TP53 突变型肿瘤,并确定 NRAS 为致癌驱动基因。
Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14.

引用本文的文献

1
Analysis of Morbidity, Mortality and Survival Pattern Following Surgery for Borderline Ovarian and Malignant Ovarian Tumour in Tertiary Care Centre.三级护理中心卵巢交界性肿瘤和恶性卵巢肿瘤手术后的发病率、死亡率及生存模式分析
J Obstet Gynaecol India. 2021 Jun;71(3):297-303. doi: 10.1007/s13224-020-01425-2. Epub 2021 Feb 19.
2
Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.与韩国和中国台湾两所大型学术机构的低级别浆液性卵巢癌预后相关的临床因素。
Sci Rep. 2020 Nov 17;10(1):20012. doi: 10.1038/s41598-020-77075-1.
3

本文引用的文献

1
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.采用 2 级系统对浆液性卵巢癌进行重新分类:一项妇科肿瘤学组研究。
Cancer. 2012 Jun 15;118(12):3087-94. doi: 10.1002/cncr.26618. Epub 2011 Nov 9.
2
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.上皮性卵巢癌的分子发病机制和卵巢外起源——改变模式。
Hum Pathol. 2011 Jul;42(7):918-31. doi: 10.1016/j.humpath.2011.03.003.
3
Global cancer statistics.全球癌症统计数据。
Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
中国低度浆液性卵巢癌患者中BRAF和KRAS突变的低频率
Diagn Pathol. 2017 Dec 22;12(1):87. doi: 10.1186/s13000-017-0679-3.
4
Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.基因共表达网络揭示了预测浆液性卵巢癌分期和分级的共享模块。
Oncotarget. 2017 Jun 27;8(26):42983-42996. doi: 10.18632/oncotarget.17785.
5
Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).低级别浆液性卵巢癌(LGSC)中下丘脑-垂体-性腺轴相关激素受体的表达
J Ovarian Res. 2017 Jan 25;10(1):7. doi: 10.1186/s13048-016-0300-5.
6
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.上皮性卵巢癌预后因素的最新进展
Int Sch Res Notices. 2014 Oct 29;2014:953509. doi: 10.1155/2014/953509. eCollection 2014.
7
A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.比较卵巢低级别浆液性癌和高级别组织学女性患者的生存分析。
Onco Targets Ther. 2014 Oct 16;7:1891-9. doi: 10.2147/OTT.S67812. eCollection 2014.
8
A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.1978年至2002年丹麦全国性浆液性“交界性”卵巢肿瘤研究:集中病理复查及与普通人群相比的总生存率
Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.
9
MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.用于潜在预测卵巢浆液性癌预后的微小RNA表达特征
Tumour Biol. 2013 Dec;34(6):3501-8. doi: 10.1007/s13277-013-0928-3. Epub 2013 Jul 9.
10
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.在一项上皮性卵巢癌的汇总前瞻性队列中,KRAS 突变状态的临床病理相关性和预后意义。
Diagn Pathol. 2013 Jun 25;8:106. doi: 10.1186/1746-1596-8-106.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
4
Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.具有砂粒体的卵巢浆液性癌的长期肿瘤学结局:卵巢上皮性癌分子发病机制的新见解。
Cancer Sci. 2010 Jun;101(6):1550-6. doi: 10.1111/j.1349-7006.2010.01556.x. Epub 2010 Mar 10.
5
The heterogeneity of epithelial ovarian cancer: getting it right.上皮性卵巢癌的异质性:正确认识它
Cancer. 2010 Mar 15;116(6):1400-2. doi: 10.1002/cncr.24926.
6
Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.肿瘤类型和亚分期可预测Ⅰ期和Ⅱ期卵巢癌的生存率:见解与启示。
Gynecol Oncol. 2010 Jan;116(1):50-6. doi: 10.1016/j.ygyno.2009.09.029. Epub 2009 Oct 12.
7
Ovarian cancer: an overview.卵巢癌:概述
Am Fam Physician. 2009 Sep 15;80(6):609-16.
8
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.卵巢低级别和高级别浆液性癌:发病机制、临床病理及分子生物学特征,以及诊断问题
Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa.
9
Gynecologic cancers.妇科癌症
Prim Care. 2009 Mar;36(1):115-30, ix. doi: 10.1016/j.pop.2008.10.001.
10
Epidemiology of ovarian cancer.卵巢癌流行病学
Methods Mol Biol. 2009;472:413-37. doi: 10.1007/978-1-60327-492-0_20.